USA flag logo/image

An Official Website of the United States Government

A Nano-pharmaceutical Platform for Creating Artificial Vaccines

Award Information

Agency:
Department of Defense
Branch:
N/A
Award ID:
Program Year/Program:
2011 / SBIR
Agency Tracking Number:
O111-H01-3056
Solicitation Year:
2011
Solicitation Topic Code:
OSD11-H01
Solicitation Number:
2011.1
Small Business Information
Parabon NanoLabs, Inc.
11260 Roger Bacon Drive Suite 406 Reston, VA 20190-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2011
Title: A Nano-pharmaceutical Platform for Creating Artificial Vaccines
Agency: DOD
Contract: W911NF-11-C-0267
Award Amount: $150,000.00
 

Abstract:

In this project, Parabon NanoLabs (PNL) will demonstrate the feasibility of extending its Essemblix(tm) Drug Development Platform, a combination of computer-aided design (CAD) software and DNA nano-fabrication technology, to produce Essemblix-V, a platform for creating artificial vaccines from a predefined set of"building block molecules"assembled on DNA origami. Given an epitope for a potential biothreat agent, Essemblix-V will allow the production of artificial epitopes (hereafter"mimotopes") that can mimic the original epitope sufficiently to bind target antibodies with high affinity. Additionally, Essemblix-V will allow mimotopes to be arranged on origami in complex presentation patterns known to elicit rapid and potent immune response via T cell-independent activation. As a proof of concept, PNL will demonstrate the feasibility of (i) enhancing its existing inSequio(tm) CAD software to support the design of mimotopes with building block molecules; and (ii) modulating, through rational design, the charge distribution and hydrophobicity of specific mimotopes, since these attributes can affect conformation and stability. Prototype mimotopes will be created for /Borrelia burgdorferi/ and ricin toxin and their affinity to specific monoclonal antibodies will be demonstrated via ELISA assay. In Phase 2, artificial vaccines will be created for theses targets and evaluated in a murine model.

Principal Investigator:

Steven Armentrout
CEO
(703) 689-9689
steve@parabon.com

Business Contact:

Paula Gawthorp-Armentrout
Corporate Secretary
(703) 689-9689
paula@parabon.com
Small Business Information at Submission:

Parabon NanoLabs, Inc.
11260 Roger Bacon Drive Suite 406 Reston, VA -

EIN/Tax ID: 262194625
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No